Molina J-M, et al. Doravirine (DOR) versus ritonavir-boosted darunavir (DRV+r): 96-week results of the randomized, double-blind, phase 3 DRIVE-FORWARD Noninferiority trial. AIDS 2018.
Impact van ‘single-room contact precautions’ op acquisitie en transmissie van MDR 'E. coli'
mrt 2019 | Bacteriële infecties